Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

AVBP

ArriVent BioPharma Inc.

May 15 • 04:00PM ET

19.50

Dollar change +1.04
Percentage change 5.63	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA IWO VTWO IWC SCHB RYLD

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	41.48%	Shs Outstand	33.49M	Perf Week	12.33%
Market Cap	653.06M	Forward P/E	-	EPS next Y	-2.74	Insider Trans	15.74%	Shs Float	19.60M	Perf Month	16.07%
Income	-96.02M	PEG	-	EPS next Q	-0.60	Inst Own	30.06%	Short Float	8.21%	Perf Quarter	-9.22%
Sales	0.00M	P/S	-	EPS this Y	90.89%	Inst Trans	-	Short Ratio	9.27	Perf Half Y	-
Book/sh	9.49	P/B	2.06	EPS next Y	7.02%	ROA	-	Short Interest	1.61M	Perf Year	-
Cash/sh	9.48	P/C	2.06	EPS next 5Y	-	ROE	-	52W Range	14.35 - 25.95	Perf YTD	-2.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-30.21%	52W High	-24.86%	Beta	-
Dividend TTM	-	Quick Ratio	32.82	Sales past 5Y	0.00%	Gross Margin	-	52W Low	35.89%	ATR (14)	1.07
Dividend Ex-Date	-	Current Ratio	32.82	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	70.92	Volatility	5.37% 7.11%
Employees	40	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	30.20
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-66.77%	Payout	-	Rel Volume	0.30	Prev Close	18.46
Sales Surprise	-	EPS Surprise	35.02%	Sales Q/Q	-	Earnings	May 08 BMO	Avg Volume	173.56K	Price	19.50
SMA20	17.29%	SMA50	10.41%	SMA200	3.52%	Trades		Volume	51,360	Change	5.63%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	H.C. Wainwright	Buy	$25
Feb-20-24	Initiated	Jefferies	Buy	$35
Feb-20-24	Initiated	Goldman	Buy	$27
Feb-20-24	Initiated	Citigroup	Buy	$30

May-08-24 12:54PM	AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	ArriVent BioPharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 04:05PM	ArriVent Appoints Kristine Peterson to its Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	ArriVent BioPharma Reports Full Year 2023 Financial Results (GlobeNewswire)
Feb-05-24 12:59PM	Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Paul Tudor Jones, Julian Robertson, Charles Edwards, Arcus Biosciences, Inc. (RCUS), Arrivent Biopharma Inc (AVBP), and More (Insider Monkey)
09:30PM	Loading…
Jan-25-24 09:30PM	ArriVent Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on identifying, licensing and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HILLHOUSE INVESTMENT MANAGEMEN	10% Owner	Jan 30 '24	Buy	18.00	555,555	9,999,990	4,484,672	Feb 01 04:47 PM
HEALY JAMES	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,696,752	Jan 31 04:10 PM
GORDON CARL L	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,513,664	Jan 31 04:11 PM
ORBIMED ADVISORS LLC	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,513,664	Jan 31 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVBP

ArriVent BioPharma Inc.

Upgrade your FINVIZ experience